Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 12/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288263 | 0.86 | NPSR1 (0.43) | CPS1MTNR1BABHD6MGLLL3MBTL1 | |
| SCHEMBL4749712 | 0.85 | RAB9A (0.46) | CPS1ABHD6MGLLL3MBTL1ALDH1A1 | |
| SCHEMBL4294973 | 0.84 | MGLL (0.40) | ABHD6MGLLL3MBTL1ALDH1A1 | |
| SCHEMBL4752309 | 0.83 | PPARG (0.48) | ABHD6MGLLL3MBTL1ALDH1A1 | |
| SCHEMBL4295179 | 0.83 | KDM4E (0.44) | ABHD6MGLLL3MBTL1ALDH1A1 | |
| SCHEMBL4751893 | 0.83 | MGLL (0.42) | CPS1MTNR1BABHD6MGLLL3MBTL1 | |
| SCHEMBL4297922 | 0.82 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1 | |
| SCHEMBL4753498 | 0.81 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1 | |
| SCHEMBL4301342 | 0.81 | ALDH1A1 (0.42) | ABHD6MGLLALDH1A1 | |
| SCHEMBL4293508 | 0.81 | ALDH1A1 (0.42) | ABHD6MGLLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CPS1 2464/4885MTNR1B 856/4885ABHD6 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.